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Type 2 diabetes or non-diabetic patients (50.3 years, vs. 69.5 and 66.6 years respec-
tively) at the time of surgery. The average cost of diabetic patients (both types) was 
more than twice the cost of non-diabetics in both glaucoma surgery (€ 7,972 vs. 
€ 3,278; p< 0.001) and cataract extractions (€ 10,668 vs. € 3,935; p= 0.031) and about 
30% higher in vitrectomies (€ 3,755 vs. € 2,869; p< 0.001). LOS was also systematically 
higher in diabetic patients (glaucoma surgery: 5.8 vs. 2.4 days; vitrectomy: 2.3 vs. 1.7 
days; cataract extraction: 14.7 vs. 3.0 days). ConClusions: The presence of diabetes 
increases dramatically both LOS and hospitalization costs in patients undergoing 
ophthalmological surgery.
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objeCtives: To estimate annual productivity loss costs attributable to having obe-
sity in working US adults with diabetes. Methods: This study applied a cross-
sectional design using the 2003-2012 Medical Expenditure Panel Survey (MEPS) data. 
Asthma patients (18-64 years old) were self-reported, had a Clinical Classification 
Codes of 0049, 050, or ICD-9-CM code of 250. To investigate the impact of having 
obesity, patients were classified as normal-weight (18.5≤ BMI< 25), overweight (25≤ 
BMI< 30), and obese (BMI≥ 30). Productivity loss costs, which were measured based 
on missed work days due to illness or injury for one year and the hourly wage, were 
estimated using a two-part model to adjust for patients with zero costs. To estimate 
the productivity loss costs attributable to having obesity, each group of costs was 
estimated by assuming everybody to be obese; these costs were then re-estimated by 
assuming everybody was normal weight, and the mean difference between the two 
estimated costs was calculated. All costs were converted to 2013 US dollars using 
the Consumer Price Index. Results: Among a total of 6,992 working adults with 
diabetes, the prevalence of normal-weight was 12.9%, overweight 30.1%, and obese 
57.0%. Annual average productivity loss costs for normal-weight and obesity in dia-
betes patients were $471(95%CI:$354-$588) and $585(95%CI:$523-$647) per patient, 
respectively. Among patients with diabetes who had loss of productivity costs, those 
with obesity had 1.02 times greater productivity loss costs than normal-weight 
patients after adjusting for patients’ demographic and clinical characteristics. The 
adjusted productivity loss costs attributable to having obesity in working diabetes 
patients was estimated at $77(95%CI:$76-$78) per patient per year. ConClusions: 
The loss of productivity costs among US diabetes patients is substantial, which is 
amplified by the presence of obesity. This study highlights the importance of obesity 
control in order to reduce costs and enhance productivity in patients with diabetes.
PDB42
LongituDinAL chAnges in MeDicAL services costs froM 2006 to 2012 
for neWLy DiAgnoseD t2D PAtients
Weng W, Liang Y, Kimball E, Hobbs T, Kong S, Sakurada B, Bouchard J
Novo Nordisk, Inc., Plainsboro, NJ, USA
objeCtives: Changes in healthcare resource utilization by Type 2 diabetes (T2D) 
patients over time are important for understanding the effects that treatment 
paradigms may have on costs of disease. This study was a longitudinal assessment 
of real-world claims data which followed changes in treatment costs for a single 
cohort (N= 35017) of newly diagnosed T2D patients. Methods: The Truven Health 
MarketScan® Database was examined for claims data from US-based T2D patients. 
Inclusion criteria were: at least 2 diagnoses according to ICD-9 codes for T2D, or 1 
T2D diagnosis plus 1 or more OAD claims, and allowing 1 possible misdiagnosis for 
type 1 diabetes, ≥ 18 years of age, continuous enrolment starting from 2006 (index 
year) to 2012 in a plan with prescription benefits, and at least 1 prescription for any 
anti-diabetic drug . All-cause costs of inpatient and outpatient services, medications, 
and supplies were analyzed. Results: From 2006-2012, total annual costs/patient 
increased from $9,817 to $12,551, adjusted to 2012 levels. Costs for outpatient ser-
vices grew 33% ($4,214-$5,645/outpatient). Outpatient emergency room utilizer costs 
rose 40% ($1,846-$2,586/utilizer). Total inpatient costs rose 47% ($19,453-$28,526), 
followed by a 36% growth of inpatient emergency room costs ($15,823-$21,526). 
Inpatient costs/1-day stay rose from $3,473 to $4,322, and inpatient ER costs/1-day 
stay increased from $2,776-$3,261. From 2006-2012, mean total days/stay/inpatient 
remained stable between 5.6 to 6.0 days, indicating annually increasing costs for 
inpatient services. Overall annual drug costs/utilizer increased 14% ($2,969-$3,389), 
as did anti-diabetic drug costs/utilizer (81%; $474-$858). Between 2006-2012, diag-
nosed T2D-assocated comorbidities increased as follows: cerebrovascular disease 
(13%-21%), peripheral vascular (3%-10%), nephropathy (3%-13%), and retinopathy 
(4%-14%). ConClusions: Costs for all types of resource utilization increased, rang-
ing from 17% to 81%, mainly driven by increased inpatient costs. Population aging 
may partly be responsible for the increased comorbidities, thus accounting for some 
increased treatment costs, along with increased drug costs.
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objeCtives: The SGLT2 inhibitor dapagliflozin (DAPA) increases glucosuria in an 
insulin-independent manner resulting in reductions in hyperglycemia, weight 
and BP with a low risk of hypoglycemia. Glipizide (GLIP) reduces hyperglycemia by 
increasing beta cell insulin secretion with risk of hypoglycaemia and weight gain. 
We conducted a cost analysis of treating patients over 4 years to two relevant com-
posite endpoints: (1) HbA1c lowering of ≤ 0.5%, no major or minor hypoglycaemic 
events and weight loss ≥ 3% and (2) HbA1c lowering of ≤ 0.5%, no major or minor 
hypoglycaemic events and weight loss ≥ 5%. Methods: The Cardiff Diabetes model 
41 841 (~EUR 1 518) per one patient. The total average cost per one type-2-diabetes 
patient was CZK 55 956 (~EUR 2.031) in 2014. ConClusions: Our data indicate that 
the cost of type 2 diabetes mellitus was CZK 55 956 (~EUR 2 031). A longitudinal study 
is, however, required to confirm the development of the average patient cost and 
take account of the cost of complications.
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objeCtives: diabetic foot syndrome (DFS) is expensive complication of diabetes 
leading to disability. There are costly innovative drugs that can make complications 
more curable. It is necessary to obtain evidences of new technologies economic ben-
efits. The aim of the study was to determine the economic burden of DFS in health 
care of the Republic of Belarus. Methods: “cost of illness” analysis for outpatient 
and inpatient treatment of DFS patients has been performed. A retrospective study 
of treatment of 15 outpatients with diabetic ulcers and 16 inpatients who under-
went amputation of different levels has been made. Direct and indirect costs were 
estimated. Average, minimal, maximal costs were calculated. All costs are given in 
euros (may, 2015). Results: out-patient direct medical costs are 259 (78 to 636) per 
patient/year. Indirect costs are 1941 (from 1022 to 4357) per patient/year. The cost 
of “big” amputation is 5248 (from 647 to 13,556) per hospitalization and 1099 (from 
282 to 3702 euros) for “small” amputations. Indirect costs range from 352 to 978 
during the period of treatment. ConClusions: Amputation usually considered 
as emergency aid in the case of DFS makes significant financial burden for hospi-
tals and health care system. Careful assesment of cost of illness of diabetes and 
it’s complications allows to expand opportunities of expansive outpatient medical 
technologies use.
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objeCtives: With the introduction and delisting of some glucose-lowering medi-
cations, pharmacological treatments in T2D have changed in the recent years and 
details of the current drug use patterns are not known. This descriptive study 
aims to describe characteristics of patients with type 2 diabetes and patterns of 
use of antihyperglycemic agents in France in 2013. Methods: A random sample 
of ≈ 600,000 patients registered in the French national health insurances reim-
bursement database was used. Patients with diabetes were identified through 
their use of glucose-lowering medication and coding of hospital stays and long-
standing condition insurance coverage in the database. Drug utilization pattern 
of antihyperglycemic agents were estimated considering prescriptions in Q4 2013 
and compared to data from Q4 2007. Results: Overall 28,708 patients with T2D 
(estimated database prevalence 4.5%, 8.8% in people aged 40 and over) were iden-
tified in 2013. Mean age was 67.5 (SD 12.9), 54.1% were male. In Q4, 41.2% of T2D 
pharmacologically treated patients received a monotherapy, 25.6% a dual therapy, 
13.7% a multi-therapy and 19.5% an insulin therapy with or without other hypo-
glycemic agents. Compared to 2007 data, a slight but significant increasing trend 
toward combination therapies and insulin was observed. The use of metformin 
increased over time especially in monotherapy (66% among monotherapy in 2013 
versus 50% in 2007). All thiazolidinediones and some sulfonylureas treatments 
were replaced by DPP-4 inhibitors and to a much lesser extent with GLP-1 ana-
logues. ConClusions: Antihyperglycemic prescription patterns in France have 
changed in recent years in parallel with the introduction of different classes 
of medications to the marketplace but probably also in an attempt to improve 
glycemic control of patients. Knowledge of real life pattern of drug utilization 
remains an important dimension to better understand therapeutic needs in T2D 
management.
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objeCtives: Ophthalmological complications (glaucoma, retinopathy, cataract) are 
frequent in patients with type I or type II diabetes and often require surgical treat-
ment. This study aimed at assessing the impact of diabetes on the hospitalization 
costs and the length of stay associated with these surgical treatments in Belgium, 
using retrospective data. Methods: The average hospitalization cost and the aver-
age length of stay (LOS) among patients hospitalized for ophthalmological surgery 
were estimated using the longitudinal IMS Hospital Disease Database (year 2013), 
including data (diagnoses, procedures, costs) on 24% of Belgian hospital beds. Stays 
were searched based on ICD-9-CM procedure codes corresponding to surgery for 
glaucoma (12.1 to 12.7), vitrectomy (14.71-14.74) and cataract extraction (13.19, 13.6). 
Patients were identified as diabetic if at least one diagnostic of diabetes (ICD-9-CM: 
249-250) had been documented during the calendar year. The impact of diabetes on 
LOS/ cost was assessed through Wilcoxon non-parametrical tests. Results: 671 
stays with surgery for glaucoma, 1,438 stays with vitrectomy and 204 stays with 
cataract extraction were retrieved in the database (with diabetic patients accounting 
for 56, 202 and 24 of these stays respectively). Patients with Type I diabetes (n= 16, 
split between glaucoma surgery and vitrectomy) were significantly younger than 
